J
José Gómez-Codina
Researcher at Instituto Politécnico Nacional
Publications - 62
Citations - 2582
José Gómez-Codina is an academic researcher from Instituto Politécnico Nacional. The author has contributed to research in topics: Lung cancer & Rituximab. The author has an hindex of 17, co-authored 59 publications receiving 2400 citations.
Papers
More filters
Journal ArticleDOI
A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer.
Rafael Rosell,José Gómez-Codina,Carlos Camps,José Maestre,J Padille,Antonio Canto,Jose Luis Mate,S Li,J. Roig,A Olazábal +9 more
TL;DR: Preoperative chemotherapy increases the median survival in patients with non-small-cell lung cancer, and the prevalence of mutated K-ras oncogenes was 15 percent among the patients receiving preoperative chemotherapy and 42 percent among those treated with surgery alone.
Journal ArticleDOI
Preresectional chemotherapy in stage IIIA non-small-cell lung cancer: a 7-year assessment of a randomized controlled trial.
Rafael Rosell,José Gómez-Codina,Carlos Camps,Jose Javier Sanchez,José Maestre,José Padilla,Antonio Canto,Albert Abad,Jordi Roig +8 more
TL;DR: In this article, the authors evaluated the potential benefit of pre-operative chemotherapy with cisplatin, ifosfamide and mitomycin over surgery alone in CT-visible N2 non-small-cell lung cancer.
Journal ArticleDOI
Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial
Rafael Rosell,Urania Dafni,Enriqueta Felip,Alessandra Curioni-Fontecedro,Oliver Gautschi,Solange Peters,Bartomeu Massuti,Ramon Palmero,Santiago Ponce Aix,Enric Carcereny,Martin Früh,Miklos Pless,Sanjay Popat,Athanasios Kotsakis,Sinead Cuffe,Paolo Bidoli,Adolfo Favaretto,Patrizia Froesch,Noemi Reguart,Javier Puente,Linda Coate,Fabrice Barlesi,Daniel Rauch,Michael Thomas,Carlos Camps,José Gómez-Codina,Margarita Majem,Rut Porta,Riyaz Shah,Emer Hanrahan,Roswitha Kammler,Barbara Ruepp,Manuela Rabaglio,M. Kassapian,Niki Karachaliou,Rachel Tam,David S. Shames,Miguel Angel Molina-Vila,Rolf A. Stahel +38 more
TL;DR: The BELIEF trial provides further evidence of benefit for the combined use of erlotinib and bevacizumab in patients with NSCLC harbouring activating EGFR mutations.
Journal ArticleDOI
Pretreatment prognostic factors for survival in small-cell lung cancer: a new prognostic index and validation of three known prognostic indices on 341 patients.
I. Maestu,M. Pastor,José Gómez-Codina,Jorge Aparicio,A. Oltra,C. Herranz,Joaquín Montalar,B. Munárriz,Gaspar Reynes +8 more
TL;DR: A new prognostic index was performed that included LDH, hypoalbuminemia, neutrophilia, disease extent and PS, which defined three prognostic groups (PG) and the feasibility of three known prognostic models was validated and demonstrated.
Journal ArticleDOI
Circulating endothelial cells and microparticles as prognostic markers in advanced non-small cell lung cancer.
Tania Fleitas,Vicenta Martínez-Sales,Virtudes Vila,Edelmiro Reganon,David Mesado,M. Martin,José Gómez-Codina,Joaquín Montalar,Gaspar Reynés +8 more
TL;DR: Elevated levels of microparticles and circulating endothelial cells correlate with prognosis, and could be useful as prognostic markers in patients with advanced non-small cell lung cancer.